Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00102089
Status:
COMPLETED
Last Update Posted:
2017-07-02
First Post:
2005-01-20
Brief Title:
HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Booster Dose of a Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine VRC-HIVADV014-00-VP in Uninfected Subjects Who Were Previously Immunized With VRC-HIVDNA009-00-VP in VRC 004
Status:
COMPLETED
Status Verified Date:
2007-10-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will test the safety and side effects of an experimental vaccine booster against HIV A vaccine is a substance given to try to create immunity or resistance to a disease or infection The vaccine used in this study is called VRC-HIVADV014-00-VP It is made from an adenovirus a common virus that causes upper respiratory infections that contains DNA genetic material of three HIV proteins Injected into a human the viral DNA instructs the body to make small amounts of some HIV proteins VRC-HIVADV014-00-VP will be given to people who previously received a vaccine called VRC-HIVDNA009-00-VP under NIH protocol 03-I-0022 Important Study participants cannot catch an adenovirus infection or HIV or AIDS from the vaccine or any proteins made from it
Healthy normal volunteers who participated in NIH protocol 03-I-0022 may be eligible for this study They must have completed three injections of 4 mg or 8 mg of VRC-HIVDNA009-00-VP without experiencing a serious side effect that was possibly related to the vaccine Candidates are screened with a medical history clinical evaluation blood and urine tests and HIV and pregnancy counseling
Participants receive one injection of VRC-HIVADV014-00-VP the day they enroll in the study study day 0 They are observed for at least 30 minutes after immunization At home they record their temperature and any symptoms they may experience including any effects at the injection site for 5 days and call a study nurse 1 or 2 days after the injection They immediately report any symptoms to the clinic staff and if necessary come to the clinic for an examination
Participants have five additional clinic visits during the study at weeks 2 4 6 12 and 24 each lasting about 2 hours At each visit they are checked for health changes or problems and are asked about medications they are taking Blood is drawn for immune function testing HLA typing a genetic test of immune system markers and other genetic factors A urine sample is collected at some visits Additional laboratory tests may be requested between visits Some participants may undergo apheresis at the week 4 visit to collect a large number of white blood cells for laboratory tests to see how the immune system responds to the study vaccine For this procedure blood is collected through a needle in an arm vein and flows through a catheter plastic tube into a machine that separates it into its components by centrifugation spinning The white cells are extracted and the rest of the blood is returned through another needle in the other arm The procedure takes about 1 to 3 hours
Participants are tested three or more times for HIV and are questioned about their sexual behavior and drug use They complete a social impact questionnaire at week 24 that includes questions about any problems they may have experienced from their participation in the study regarding such things as insurance health care friends family employment housing education or government agencies
Healthy normal volunteers who participated in NIH protocol 03-I-0022 may be eligible for this study They must have completed three injections of 4 mg or 8 mg of VRC-HIVDNA009-00-VP without experiencing a serious side effect that was possibly related to the vaccine Candidates are screened with a medical history clinical evaluation blood and urine tests and HIV and pregnancy counseling
Participants receive one injection of VRC-HIVADV014-00-VP the day they enroll in the study study day 0 They are observed for at least 30 minutes after immunization At home they record their temperature and any symptoms they may experience including any effects at the injection site for 5 days and call a study nurse 1 or 2 days after the injection They immediately report any symptoms to the clinic staff and if necessary come to the clinic for an examination
Participants have five additional clinic visits during the study at weeks 2 4 6 12 and 24 each lasting about 2 hours At each visit they are checked for health changes or problems and are asked about medications they are taking Blood is drawn for immune function testing HLA typing a genetic test of immune system markers and other genetic factors A urine sample is collected at some visits Additional laboratory tests may be requested between visits Some participants may undergo apheresis at the week 4 visit to collect a large number of white blood cells for laboratory tests to see how the immune system responds to the study vaccine For this procedure blood is collected through a needle in an arm vein and flows through a catheter plastic tube into a machine that separates it into its components by centrifugation spinning The white cells are extracted and the rest of the blood is returned through another needle in the other arm The procedure takes about 1 to 3 hours
Participants are tested three or more times for HIV and are questioned about their sexual behavior and drug use They complete a social impact questionnaire at week 24 that includes questions about any problems they may have experienced from their participation in the study regarding such things as insurance health care friends family employment housing education or government agencies
Detailed Description:
Study Design This is a Phase I open-label study to examine safety tolerability and immune response of a multiclade HIV adenoviral vector vaccine as a booster vaccination in uninfected adults The hypothesis is that this vaccine will be safe as a booster vaccine and elicit immune responses to HIV The primary objective is to evaluate the safety and tolerability of a VRC-HIVADV014-00-VP booster vaccination in uninfected subjects who previously received 3 injections of VRC-HIVDNA009-00-VP more than one year prior to the study vaccination The secondary objectives include immunogenicity evaluations and adenovirus serotype 5 Ad5 antibody titers and social impacts Exploratory evaluations include epitope mapping and other immunogenicity evaluations
Product Description VRC-HIVADV014-00-VP is a recombinant product composed of 4 adenoviral vectors Ad in a 3111 ratio that encode the HIV-1 GagPol polyprotein from clade B and HIV-1 Env glycoproteins from clades A B and C respectively
Subjects Healthy adult volunteers who previously received three injections of VRC-HIVDNA009-00-VP at a dosage of 4 mg or 8 mg in the VRC 004 study 03-I-0022 subjects in these groups were between 20 and 39 years old at time of enrollment in VRC 004 those who participate in VRC 009 will be approximately 1-3 years older at the time of enrollment into VRC 009
Study Plan Up to thirty-two volunteers will receive one 1 mL injection of the study agent at a dosage of 1 x 1010 PU IM in a deltoid muscle Safety and immunogenicity will be evaluated by follow-up visits over the subsequent 24 weeks The peripheral blood mononuclear cell PBMC sample for immunogenicity studies collected at Week 4 after vaccination will be obtained by apheresis if the subject is willing and eligible for apheresis and an apheresis appointment can be conveniently scheduled in the interval specified otherwise PBMCs will be obtained from 80 mL blood collected by phlebotomy
Study Duration Subjects will be evaluated at 6 or more clinical visits for 24 weeks after the study injection
Study Endpoints The primary endpoint is safety of the vaccine administered at a dose of 1 x 1010 particle units PU by intramuscular injection Secondary endpoints are immunogenicity as indicated by HIV-specific antibody and cellular immune responses through Week 6 Ad5 antibody titer at Week 0 and Week 4 and social impact at Week 24 Exploratory analyses of immunogenicity at Weeks 12 and 24 Ad5 antibody titer at Week 24 and epitope mapping of the CD8 and CD4 T cell responses at Week 4
Product Description VRC-HIVADV014-00-VP is a recombinant product composed of 4 adenoviral vectors Ad in a 3111 ratio that encode the HIV-1 GagPol polyprotein from clade B and HIV-1 Env glycoproteins from clades A B and C respectively
Subjects Healthy adult volunteers who previously received three injections of VRC-HIVDNA009-00-VP at a dosage of 4 mg or 8 mg in the VRC 004 study 03-I-0022 subjects in these groups were between 20 and 39 years old at time of enrollment in VRC 004 those who participate in VRC 009 will be approximately 1-3 years older at the time of enrollment into VRC 009
Study Plan Up to thirty-two volunteers will receive one 1 mL injection of the study agent at a dosage of 1 x 1010 PU IM in a deltoid muscle Safety and immunogenicity will be evaluated by follow-up visits over the subsequent 24 weeks The peripheral blood mononuclear cell PBMC sample for immunogenicity studies collected at Week 4 after vaccination will be obtained by apheresis if the subject is willing and eligible for apheresis and an apheresis appointment can be conveniently scheduled in the interval specified otherwise PBMCs will be obtained from 80 mL blood collected by phlebotomy
Study Duration Subjects will be evaluated at 6 or more clinical visits for 24 weeks after the study injection
Study Endpoints The primary endpoint is safety of the vaccine administered at a dose of 1 x 1010 particle units PU by intramuscular injection Secondary endpoints are immunogenicity as indicated by HIV-specific antibody and cellular immune responses through Week 6 Ad5 antibody titer at Week 0 and Week 4 and social impact at Week 24 Exploratory analyses of immunogenicity at Weeks 12 and 24 Ad5 antibody titer at Week 24 and epitope mapping of the CD8 and CD4 T cell responses at Week 4
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 05-I-0081 | None | None | None |